Accentia plans drug production plant; Sanofi/Merck JV gets animal health chief;

 @FierceBiotech: Is a bidding war for Genzyme looming? Report | Follow @FierceBiotech

> Accentia Biopharmaceuticals plans to revive discussions on a proposed production plant once it emerges from bankruptcy, according to a report in the St. Louis Business Journal. The plant would produce the experimental Revimmune for MS. Story

> Sanofi-Aventis and Merck have named Raul Kohan as the new CEO of their new joint venture on animal health. Kohan is currently president of Intervet/Schering-Plough. Report

> Ampio Pharmaceuticals has struck a deal to acquire DMI BioSciences, giving Ampio access to all rights, royalties and patents associated with DMI's drugs for male sexual dysfunction including premature ejaculation. Release

> Prolias Technologies, which supplies cancer researchers with research reagents, has spun out of Prolias, LLC. Release

And Finally... Childhood cancer survival is associated with increased risk of long-term abnormalities in cardiac function, according to a report in the July 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Release